Bruton tyrosine kinase inhibitors for multiple sclerosis
Current therapies for multiple sclerosis (MS) reduce both relapses and relapse-associated
worsening of disability, which is assumed to be mainly associated with transient infiltration of …
worsening of disability, which is assumed to be mainly associated with transient infiltration of …
Epidemiology and pathophysiology of multiple sclerosis
M Ward, MD Goldman - CONTINUUM: Lifelong Learning in …, 2022 - journals.lww.com
Epidemiology and Pathophysiology of Multiple Sclerosis : CONTINUUM: Lifelong Learning in
Neurology Account Register Activate Subscription Help Subscribe American Academy of …
Neurology Account Register Activate Subscription Help Subscribe American Academy of …
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
SARS-CoV-2 messenger RNA vaccination in healthy individuals generates immune
protection against COVID-19. However, little is known about SARS-CoV-2 mRNA vaccine …
protection against COVID-19. However, little is known about SARS-CoV-2 mRNA vaccine …
[HTML][HTML] Ublituximab versus teriflunomide in relapsing multiple sclerosis
L Steinman, E Fox, HP Hartung, E Alvarez… - … England Journal of …, 2022 - Mass Medical Soc
Background The monoclonal antibody ublituximab enhances antibody-dependent cellular
cytolysis and produces B-cell depletion. Ublituximab is being evaluated for the treatment of …
cytolysis and produces B-cell depletion. Ublituximab is being evaluated for the treatment of …
Therapeutic advances in multiple sclerosis
Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system that
causes significant disability and healthcare burden. The treatment of MS has evolved over …
causes significant disability and healthcare burden. The treatment of MS has evolved over …
Thinking outside the box: non-canonical targets in multiple sclerosis
Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system that
causes demyelination, axonal degeneration and astrogliosis, resulting in progressive …
causes demyelination, axonal degeneration and astrogliosis, resulting in progressive …
Functional immune cell–astrocyte interactions
Astrocytes are abundant glial cells in the central nervous system (CNS) that control multiple
aspects of health and disease. Through their interactions with components of the blood …
aspects of health and disease. Through their interactions with components of the blood …
Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity
A small proportion of multiple sclerosis (MS) patients develop new disease activity soon after
starting anti-CD20 therapy. This activity does not recur with further dosing, possibly reflecting …
starting anti-CD20 therapy. This activity does not recur with further dosing, possibly reflecting …
Emerging therapies to target CNS pathophysiology in multiple sclerosis
The rapidly evolving therapeutic landscape of multiple sclerosis (MS) has contributed to
paradigm shifts in our understanding of the biological mechanisms that contribute to CNS …
paradigm shifts in our understanding of the biological mechanisms that contribute to CNS …
Preclinical autoimmune disease: a comparison of rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and type 1 diabetes
G Frazzei, RF van Vollenhoven, BA de Jong… - Frontiers in …, 2022 - frontiersin.org
The preclinical phase of autoimmune disorders is characterized by an initial asymptomatic
phase of varying length followed by nonspecific signs and symptoms. A variety of …
phase of varying length followed by nonspecific signs and symptoms. A variety of …